Clinical trial
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or…
NCT00134069 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00134069 |
|---|---|
| Title | Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer |
| Official title | Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination With Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, cetuximab, irinotecan hydrochloride |
| Enrollment | 48 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2010 |
| Completion | Dec 1, 2011 |
| First posted | Aug 24, 2005 |
| Last update posted | Apr 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: